Genzyme Receives Complete Response, Warning Letters For Lumizyme
Executive Summary
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
You may also be interested in...
Follow-On Biologics Debate May Divide PhRMA On Comparability Protocols
PhRMA President Tauzin acknowledges “there’s a little difference of opinion” among membership about what the criteria for interchangeability should be.
Follow-On Biologics Debate May Divide PhRMA On Comparability Protocols
PhRMA President Tauzin acknowledges “there’s a little difference of opinion” among membership about what the criteria for interchangeability should be.
Rationing Of Genzyme’s Myozyme In Europe Likely Through April Due To Supply Constraints
Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.